Kwangdong Pharmaceutical Co 009290.KS · KRW

Its shares trade on KRX under the ticker 009290.KS. It has been listed since 17 November 1989. In the fiscal year to 31 December 2025, it reported revenue of ₩1.66trn and net income of ₩20.97bn. At that date it held total assets of ₩1.32trn and shareholders' equity of ₩655.58bn.

Kwang Dong Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The firm operates its business through five segments. The Mineral Water Business segment supplies drinking spring water under Samdasoo brand. The Distribution Business segment distributes health drinks under brand names of Vita500 and Corn Silk Tea. The Pharmacy Business segment provides Chinese prescription cold medicines, hypertension medicines, cerebral apoplexy medicines and health drinks. The Hospital Business segment offers anticancer agents, blood vessel adjuvants, vitamin D injections and others. The Other segment provides products which not covered by Pharmacy, Hospital and Distribution segments.

Figures and description from our data supplier, not checked against the company's own report.

• Seong Won ChoiPresident, Chief Executive Officer, Director, since 2013
• Hyeon Sik KimVice President, Director, since 2008
• Gwa Gyun MoVice President, Director
• Yeong Deok GiVice President
• Sang Eon ChoManaging Director
• Yin Jae LeeManaging Director, since 2012
• Chun Sik ChoiInternal Auditor
• Bo Hyeong LeeAssistant Managing Director
• Cheol Su ParkAssistant Managing Director, since 2009
• Ju Hyeong ParkInternal Auditor
• Sang Yeong ParkAssistant Managing Director
• Do Hui WonInternal Auditor

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.